eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Chronic, Prevalent Diseases & Aging
Team
Group Leader
Antonio Julia Cano
Principal Investigator (PI)
Josefina Cortés, Ernesto Trallero, José Alegre, Juan José de Agustín de Oro, María López, Cristina Solé, Jesús Castro, Adrià Aterido, Jordi Lladós, Nuria Palau, Raül Tortosa
Researchers
Mireia Barceló, Alba Erra, Andrea Pluma, Ramón Sanmartín, Miriam Almirall, Mayte Serrat, Mireia López, Xabier Michelena, Alejandro Gómez, Estefanía Moreno
PhD Students
Luis Coronel, Helena Borrell, Rafael Touriño, María Pascual, Esther Espartal, Sebastián Sandoval, Judith Fernández
Lab Technicians
Edgar Núñez, Aitor Ruiz, Erica Téllez, Blanca Joseph
Nursing and Technical Staff
Montserrat Sender, Hugo Fernando Ávalos, Ana Daniela Ulloa, Carlos Jorge Alcaraz, Adriana Cabrera, Natalia Nogué, Carlos Junco, Alba Frias, Ares Sellés, Josep Masramón, Viviana Sánchez, María Royo, Edgar Núñez, Aitor Ruiz, Erica Téllez, Blanca Joseph, Marta Musté, Ana Roig, Natalia Boix, Mercè Fabregat, Elena Granell
Publications
COVID-19 Host Genetics Initiative (Marsal S, Julià A)
COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19
Nature. 2023 Sep;621(7977):E7-E26
DOI: 10.1038/s41586-023-06355-3
IF: 64.8
Pinal-Fernandez I, Quintana A, Milisenda JC, Casal-Dominguez M, Muñoz-Braceras S, Derfoul A, Torres-Ruiz J, Pak K, Dell'Orso S, Naz F, Gutierrez-Cruz G, Milone M, Shelly S, Duque-Jaimez Y, Tobias-Baraja E, Matas-Garcia A, Garrabou G, Padrosa J, Ros J, Trallero-Araguás E, Walitt B, Christopher-Stine L, Lloyd TE, Zhao C, Swift S, Rajan A, Grau-Junyent JM, Selva-O'Callaghan A, Liewluck T, Mammen AL
Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis
Ann Rheum Dis. 2023 Jun;82(6):829-836
DOI: 10.1136/ard-2022-223792
IF: 27.4
Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller SC, Cortes-Hernandez J, Connors JM, Kanthi Y, Krumholz HM, Middeldorp S, Falanga A, Cushman M, Goldhaber SZ, Garcia DA, Bikdeli B
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials
J Am Coll Cardiol. 2023 Jan 3;81(1):16-30
DOI: 10.1016/j.jacc.2022.10.008
IF: 24.4
Lacasa M, Alegre-Martin J, Sentañes RS, Varela-Sende L, Jurek J, Castro-Marrero J.
Yeast Beta-Glucan Supplementation with Multivitamins Attenuates Cognitive Impairments in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Nutrients 2023; 15(21):4504
DOI: 10.3390/nu15214504
IF: 5.9
Projects
Decision on optimal combinatorial therapies in IMIDs using systems approaches. DOCTIS
Principal Investigator: Sara Marsal Barril
Agency: European Comission H2020. H2020-SCH1-BHC-02-2019. https://cordis.europa.eu/project/id/848028
Funding: 6,260,050 €
Period: 01/01/2020 – 31/12/2025
Artritis reumatoide: de la fase preclínica a la enfermedad activa. Caracterización de los cambios sistémicos y en el tejido sinovial en el establecimiento de la enfermedad ACPA-positiva
Principal Investigator: Sara Marsal Barril / María López Lasanta
Agency: Instituto de Salud Carlos III (PI23/01372)
Funding: 250,000 €
Period: 01/01/2023 - 01/01/2026
Caracterización de las células patogénicas del músculo y piel de pacientes con Dermatomiositis y Síndrome Antisintetasa y estudio de aplicabilidad traslacional.
Principal Investigator: Ernesto Trallero Araguas
Agency: Instituto de Salud Carlos III (PI22/00708)
Funding: 135,520 €
Period: 01/01/2023 - 31/12/2025
Sjögren Syndrome and Atopic Dermatitis cohorts’ generation and multi-omics characterization (SSAD project)
Principal Investigator: Sara Marsal Barril, José Luis Andreu, Josep Manuel Carrascosa
Agency: IMIDomics Inc.
Funding: 1,680,000 €
Period: 26/06/2023– 26/06/2025
Inmunomonitorización personalizada para estratificar los pacientes con lupus eritematoso sistémico
Principal Investigator: Cortes Hernández, Josefina
Agency: Instituto de Salud Carlos III (PI21/00287)
Funding: 141.570€
Period: 01/01/2022 - 31/12/2024
Patents
METHOD TO PREDICT THE LACK OF RESPONSE TO ANTI-TNF ALPHA THERAPIES
Priority Number: PCT/EP2014/066604 (US)
Priority Date: 1/08/2014
Applicants: 66% VHIR, 33,3 % H. Clínic
RISK LOCUS FOR PSORIATIC ARTHRITIS
Priority Number: 62/151,952 (PCT)
Priority Date: 23/04/2015
Applicants: VHIR, CLINIC, IGTP
METHOD TO PREDICT RESPONSE TO TREATMENT WITH ANTI-TNF ALPHA AGENTS
Priority Number: EP14179452.9 (PCT)
Priority Date: 1/08/2014
Applicants: VHIR
Pronóstico de respuesta al tratamiento con anti-TNFalfa en pacientes de artritis reumatoide
Priority Number: P201330650 (PCT)
Priority Date: 3/05/2013
Applicants: VHIR
METODO IN VITRO Y KIT PARA EL PRONOSTICO O PREDICCION DE LA RESPUESTA POR PARTE DE PACIENTES CON ARTRITIS REUMATOIDE AL TRATAMIENTO CON AGENTES BLOQUEANTES DEL FACTOR TNF alfa (INFLIXIMAB)
Priority Number: P200802713 (ES)
Priority Date: 24/09/2008
Applicants: VHIR
